📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
44 announcements match the current filters (relevance ≥ 5).
Glenmark Launches Epinephrine Injection in USA Targeting $67.6 Million Market
Glenmark Pharmaceuticals Inc., USA has launched Epinephrine Injection USP (30 mg/30 mL) Multiple-Dose Vial in the United States. This product is bioequivalent and therapeutically equivalent to the reference drug from BPI Labs, LLC. The launch targets a market with annual sales of approximately $67.6 million as of October 2025. This move is intended to strengthen Glenmark's institutional channel portfolio and its presence in the North American generics market.
Key Highlights
Launched Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial in the US market.
Targets an addressable market size of approximately $67.6 million in annual sales.
Product is therapeutically equivalent to BPI Labs, LLC’s reference listed drug (NDA 205029).
Aims to expand the company's footprint within the US institutional channel for injectable products.
👀 What to Watch
Investors should view this as a positive step in Glenmark's US generic strategy, contributing to steady revenue growth. Monitor the company's market share gains in the injectables segment over the coming quarters.
Glenmark Secures Exclusive Rights for Lung Cancer Drug Aumolertinib in $1 Billion Deal
Glenmark's subsidiary, GSSA, has entered into an exclusive licensing agreement with Hansoh Pharma for Aumolertinib, a third-generation lung cancer treatment. The deal grants Glenmark rights across the Middle East, Africa, Southeast Asia, Australia, and Russia/CIS. Glenmark will pay a low double-digit million USD upfront, with potential milestone payments exceeding $1 billion plus tiered royalties. This strategic move significantly bolsters Glenmark's oncology portfolio with a drug already approved by the UK MHRA and China's NMPA.
Key Highlights
Exclusive rights for Aumolertinib in Middle East, Africa, SE Asia, Australia, and Russia/CIS.
Upfront payment of low double-digit million USD to Hansoh Pharma.
Potential regulatory and commercial milestones totaling over US$1 billion.
Aumolertinib is a third-generation EGFR-TKI approved for various non-small cell lung cancer indications.
The drug is already marketed as Ameile in China and Aumseqa in the United Kingdom.
👀 What to Watch
Investors should view this as a strong strategic expansion into the high-growth oncology segment. Monitor the commercial rollout and regulatory approvals in the newly licensed territories for long-term revenue impact.
Glenmark to Launch Leucovorin Calcium Injection in US; Targets $16.8 Million Market
Glenmark Pharmaceuticals Inc., USA is set to launch Leucovorin Calcium for Injection USP (350 mg/vial) in the United States in December 2025. The product is a bioequivalent and therapeutically equivalent version of Hospira's reference drug. According to IQVIA data, the annual market for this specific injection was approximately $16.8 million for the 12-month period ending October 2025. This launch aligns with Glenmark's strategy to expand its institutional channel portfolio and provide affordable alternatives in the North American market.
Key Highlights
Launch of Leucovorin Calcium for Injection USP, 350 mg/vial in the US market starting December 2025.
Targets an annual market size of approximately $16.8 million based on IQVIA sales data.
Product is bioequivalent to the reference listed drug (RLD) from Hospira, Inc.
Expansion of the company's institutional channel portfolio in North America.
Strengthens Glenmark's presence in the oncology-supportive care segment.
👀 What to Watch
Investors should monitor the ramp-up of Glenmark's US generic portfolio, as consistent small-to-mid-sized launches contribute to steady revenue growth in the North American segment. No immediate action is required as the market size is relatively modest compared to the company's total revenue.
Glenmark's Aurangabad Facility Receives Zero Observations from US FDA Inspection
Glenmark Pharmaceuticals has successfully completed a US FDA Pre-Approval Inspection (PAI) at its formulations manufacturing facility in Chhatrapati Sambhajinagar (Aurangabad). The inspection was conducted from November 24 to November 28, 2025, and concluded with zero Form 483 observations. This clean audit report is a significant positive for the company, as it indicates full compliance with US regulatory standards. It clears a major hurdle for the approval and launch of new products from this facility into the US market.
Key Highlights
US FDA completed a Pre-Approval Inspection (PAI) at the Aurangabad formulations facility.
The inspection took place over five days from November 24 to November 28, 2025.
The audit concluded with zero Form 483 observations, the best possible regulatory outcome.
Successful inspection paves the way for future product approvals and exports to the US market.
👀 What to Watch
Investors should view this as a strong positive development that reduces regulatory risk and supports future growth in the US market. No immediate action is required other than maintaining a positive outlook on the stock's compliance profile.
